FGFR-mediated activation of the PI3K/AKT pathway is also observed in cancer cells during BRAF (serine/threonine-protein kinase B-raf) or MEK (mitogen-activated protein kinase kinase) inhibitors treatment [62,86,87]. This evidence concerns the gene AKT1 and cancer.